000 04044nam a22003255i 4500
999 _c402851
_d402851
001 402851
003 ES-MaUEC
005 20240710120721.0
006 a||||fo|||| 00| 0
007 cr nn 008mamaa
008 231130s2023 sz | fo |||| 0|eng d
020 _a9783031316944
024 7 _a10.1007/978-3-031-31694-4
_2doi
040 _aES-MaUEC
_bspa
_cES-MaUEC
_dES-MaUEC
050 4 _aRS199.5
_b2023 EB
245 0 0 _aExploring Drug Delivery to the Peritoneum
_cedited by Ranjita Shegokar
250 _a1st ed. 2023
264 1 _aCham
_bSpringer International Publishing
_c2023
300 _a1 recurso en línea
336 _atexto
_btxt
_2rdacontent
337 _aelectrónico
_bc
_2rdamedia
338 _arecurso electrónico
_bcr
_2rdacarrier
505 0 _aChapter 1: Peritoneal Organ-Anatomical and Physiological Considerations -- Chapter 2: drug delivery platforms for intra-peritoneal delivery focusing primarily on need, delivery systems, clinical progress, market and regulatory aspects -- Chapter 3: Liposomes and Lipid Nanoparticles as Peritoneal Drug Delivery Systems -- Chapter 4: Nano and micro/medicines for intraperitoneal therapy in ovarian cancer: critical overview and focus on pharmaceutical manufacturing under cGMP -- Chapter 5: Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC): Promising Strides from India -- Chapter 6: HIPEC: Concept and Fundamentals in Colorectal C{acute}ancer Peritoneal Mestatasis Treatment -- Chapter 7: Peritoneal Implants and Drug Delivery -- Chapter 8: Importance of Computational Models in Development of Intrapertitoneal Administration based Drug Delivery Systems for Solid Tumors -- Chapter 9: Drug Delivery Systems for peritonium : current status and Future perspectives -- Chapter 10: Exploring the Intraperitoneal Route in a New Way for Preclinical Testing.
520 _aThe Peritoneal cavity (PC) is the key metastatic site for intra-abdominal malignancies (e.g., GI tract and rectal cancer). PC sites can be used to target several other diseases where lymphatic drug delivery is desired without dumping large amounts of the drug. Until recently, it was thought that treatment with curative intent was impossible but that was challenged by the introduction of cytoreductive surgery (CRS), heated intraperitoneal chemotherapy (HIPEC), and PIPAC (pressurized intraperitoneal aerosol chemotherapy). Recently, a growing number of preclinical and clinical studies advocate intraperitoneal (IP) chemotherapy as an alternative post-operative therapy for cancer. Although their effectiveness has been proven both experimentally and clinically, there is still little understanding of the role of drug delivery systems in targeting drugs in the intraperitoneal (IP) cavity. There are two main challenges posed to such therapies 1) the complexity of IP cavity and 2) the drug transport dynamics e.g., the residence time of small molecular weight drugs, the fate of delivery systems (both nano and micro), etc. The present book is a link between pharmaceutical scientists (drug formulators), clinicians, and toxicologists. This book also provides a new perspective to researchers to divert or guide their research in an optimal way. Exploring Drug Delivery to the Peritoneum serves as a platform for upcoming technologies especially in the medical devices sector to face up and show potential in delivering drugs to IP cavity. It is a chance for commercial partners like insurance companies and the pharma industry to explore the old administration route in a new way. .
988 _aSpringer_Medicine_2023
650 7 _2embne
_9667667
_aSistemas de liberación de fármacos
856 4 0 _uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-031-31694-4
_zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942 _2lcc
_cLE
998 _b07/2024
_dz
_ean
_zSI